Exelixis
EXEL
#1680
Rank
โ‚น858.35 B
Marketcap
โ‚น3,006
Share price
2.24%
Change (1 day)
66.34%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Exelixis (EXEL) - Net assets

Net assets on the balance sheet as of September 2024 : โ‚น192.05 Billion

According to Exelixis's latest financial reports the company has โ‚น192.05 Billion in net assets.
A companyโ€™s net assets is the sum of its assets minus the sum of its liabilities.

Exelixis - Net assets on balance sheet (from 2001 to 2024)

Net assets by year

Year Net assets Change
2023-12-31$โ‚น188.46 B-8.47%
2022-12-31$โ‚น205.91 B25.15%
2021-12-31$โ‚น164.53 B19.73%
2020-12-31$โ‚น137.42 B14.31%
2019-12-31$โ‚น120.22 B33.55%
2018-12-31$โ‚น90.02 B394.76%
2017-12-31$โ‚น18.19 B199.77%
2016-12-31$โ‚น6.06 B-164.86%
2015-12-31$-โ‚น9.36 Billion28.58%
2014-12-31$-โ‚น7.28 Billion-277.84%
2013-12-31$โ‚น4.09 B-74.79%
2012-12-31$โ‚น16.23 B238.53%
2011-12-31$โ‚น4.79 B-146.86%
2010-12-31$-โ‚น10.24 Billion34.68%
2009-12-31$-โ‚น7.6 Billion180.93%
2008-12-31$-โ‚น2.71 Billion-180.58%
2007-12-31$โ‚น3.35 B-16.38%
2006-12-31$โ‚น4.01 B55.65%
2005-12-31$โ‚น2.57 B17.49%
2004-12-31$โ‚น2.19 B-70.15%
2003-12-31$โ‚น7.35 B-12.85%
2002-12-31$โ‚น8.43 B-26.3%
2001-12-31$โ‚น11.44 B

Net assets for similar companies or competitors

Company Net assets differencediff. Country
โ‚น1.519 T 691.26%๐Ÿ‡ฌ๐Ÿ‡ง UK
โ‚น6.604 T 3,339.00%๐Ÿ‡ซ๐Ÿ‡ท France
โ‚น3.761 T 1,858.32%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น1.451 T 655.90%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น635.31 B 230.80%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น5.921 T 2,983.30%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น7.812 T 3,967.73%๐Ÿ‡บ๐Ÿ‡ธ USA
-โ‚น58.58 Million-100.03%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น2.43 B-98.73%๐Ÿ‡บ๐Ÿ‡ธ USA